A 52-week, open label, parallel group, multicentre, phase III, randomised controlled trial to compare the efficacy and safety of salbutamol metered dose inhaler taken as required for relief of symptoms, and budesonide/formoterol Turbuhaler taken as required for relief of symptoms, and regular budesonide Turbuhaler plus salbutamol metered dose inhaler taken as required for relief of symptoms, in adult patients with asthma.

Trial Profile

A 52-week, open label, parallel group, multicentre, phase III, randomised controlled trial to compare the efficacy and safety of salbutamol metered dose inhaler taken as required for relief of symptoms, and budesonide/formoterol Turbuhaler taken as required for relief of symptoms, and regular budesonide Turbuhaler plus salbutamol metered dose inhaler taken as required for relief of symptoms, in adult patients with asthma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Salbutamol
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms Novel START
  • Most Recent Events

    • 18 Sep 2017 Planned End Date changed from 30 Sep 2017 to 30 Aug 2018.
    • 18 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Apr 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top